BioPharma

With liquid biopsy, sensitivity matters

Sysmex Inostics industry-leading sensitivity for liquid biopsy

Liquid biopsies: from here to beyond

Key differences between HPV-positive and HPV-negative head and neck squamous cell carcinomas (HNSCC)

Sysmex Inostics & QIAGEN Highlight Cancer Companion Diagnostics Alliance at ASCO 2022

Two poster presentations utilizing Sysmex Inostics technology to be featured

Sysmex Inostics Expands Blood Test Offerings for Detection of Acute Myeloid Leukemia

Sysmex Inostics Introduces CLIA-Validated Highly Sensitive HNSCC-SEQ Testing Services for Head and Neck Cancer at the 2022 Molecular Medicine Tri-Conference

Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, will introduce HNSCC-SEQ, a highly sensitive Plasma-Safe-SeqS and Next Generation Sequencing (NGS) assay service for head and neck squamous cell carcinomas (HNSCC), at the annual 2022 Molecular Medicine Tri-Conference being held Monday, February 21st through Wednesday, February 23rd in San Diego, California. The assay has a turn-around-time of 7-10 days and is available to researchers and clinicians.